Virginia Tech researchers have shown that memory loss in aging may be reversible. Using CRISPR tools, they corrected molecular disruptions in the hippocampus and amygdala, restoring memory in older ...

Jarome and his team found that aging disrupts K63 polyubiquitination in two distinct areas of the brain. In the hippocampus, ...

Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Health Secretary Robert F. Kennedy Jr. called the treatment 'a powerful glimpse into the future of personalized medicine' ...

VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

AI drug developer partners with big pharma and Amazon, expects Korea collaborations AION Labs builds start‑ups with big ...

Leading scientists and bioethicists are urging the creation of an international oversight body to monitor advances in human ...

Memory problems may not be an unavoidable part of getting older. New findings from Virginia Tech reveal that age-related memory loss stems from ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!